NYSE:USNA

USANA Health Sciences Stock Forecast, Price & News

$97.35
-1.11 (-1.13 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$96.32
$98.95
50-Day Range
$88.80
$101.44
52-Week Range
$68.30
$102.96
Volume92,921 shs
Average Volume116,653 shs
Market Capitalization$2.01 billion
P/E Ratio18.03
Dividend YieldN/A
Beta0.98
30 days | 90 days | 365 days | Advanced Chart
Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryPersonal Products
SectorMedical
CUSIP90328M10
Phone801-954-7100
Employees1,943
Year FoundedN/A

Sales & Book Value

Annual Sales$1.06 billion
Cash Flow$7.04 per share
Book Value$16.25 per share

Profitability

Net Income$100.53 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap$2.01 billion
Next Earnings Date7/20/2021 (Estimated)
OptionableOptionable

Headlines

See More Headlines
USANA Health Sciences logo

About USANA Health Sciences

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

65th out of 2,043 stocks

Medicinals & Botanicals Industry

1st out of 33 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

Is USANA Health Sciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" USANA Health Sciences stock.
View analyst ratings for USANA Health Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than USANA Health Sciences?

Wall Street analysts have given USANA Health Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but USANA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for USANA Health Sciences
.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday, April, 27th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by $0.12. USANA Health Sciences had a net margin of 10.57% and a trailing twelve-month return on equity of 32.91%.
View USANA Health Sciences' earnings history
.

How has USANA Health Sciences' stock been impacted by Coronavirus?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, USNA shares have increased by 39.3% and is now trading at $97.35.
View which stocks have been most impacted by COVID-19
.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences declared that its Board of Directors has authorized a stock buyback program on Tuesday, February 9th 2021, which permits the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 8.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's leadership believes its shares are undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 6.150-6.500 for the period, compared to the Thomson Reuters consensus estimate of $6.280. The company issued revenue guidance of $1.24 billion-$1.28 billion, compared to the consensus revenue estimate of $1.24 billion.

What price target have analysts set for USNA?

2 brokerages have issued 1 year price objectives for USANA Health Sciences' stock. Their forecasts range from $126.00 to $126.00. On average, they expect USANA Health Sciences' stock price to reach $126.00 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts' price targets for USANA Health Sciences
or view top-rated stocks among Wall Street analysts.

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:
  • Mr. Kevin G. Guest, Chairman & CEO (Age 58, Pay $1.64M)
  • Mr. Jim Brown, Pres (Age 52, Pay $1.07M)
  • Dr. Myron W. Wentz, Founder & Chairman Emeritus (Age 80)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 51, Pay $803.36k)
  • Mr. Walter Noot, Chief Operating Officer (Age 55, Pay $776.54k)
  • Mr. David Mulham, Chief Sales Officer (Age 61, Pay $793.19k)
  • Dr. John Cuomo, Exec. Director of Product Devel. & Technology
  • Dr. Robert A. Sinnott, Chief Scientific Officer (Age 56)
  • Mr. Patrique Richards, Exec. Director of Investor Relations & Bus. Devel.
  • Mr. P. Joshua Foukas, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 45)

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences CEO Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among USANA Health Sciences' employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of USANA Health Sciences' key competitors?

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.36%), Assenagon Asset Management S.A. (0.33%), Robeco Institutional Asset Management B.V. (0.22%), Rhumbline Advisers (0.17%), Swiss National Bank (0.14%) and Exchange Traded Concepts LLC (0.08%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences
.

Which institutional investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., Robeco Institutional Asset Management B.V., State of Alaska Department of Revenue, New York State Teachers Retirement System, Texas Permanent School Fund, Strs Ohio, Comerica Bank, and The Manufacturers Life Insurance Company . Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Feng Peng, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences
or view top insider-selling stocks.

Which institutional investors are buying USANA Health Sciences stock?

USNA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Assenagon Asset Management S.A., Exchange Traded Concepts LLC, Denali Advisors LLC, Pacer Advisors Inc., 6 Meridian, Janney Montgomery Scott LLC, and Everence Capital Management Inc..
View insider buying and selling activity for USANA Health Sciences
or or view top insider-buying stocks.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $97.35.

How much money does USANA Health Sciences make?

USANA Health Sciences has a market capitalization of $2.01 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis.

How many employees does USANA Health Sciences have?

USANA Health Sciences employs 1,943 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

Where are USANA Health Sciences' headquarters?

USANA Health Sciences is headquartered at 3838 West Parkway Blvd, Salt Lake City UT, 84120.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]


This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.